Watermark
  Back to Search Results

BGB-A317-301

Completed

A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

BeOne Study ID Info icon SVG graphic used for tooltips or additional information.

BGB-A317-301

ClinicalTrials.gov ID Info icon SVG graphic used for tooltips or additional information.

NCT03412773

EudraCT or EUCT Number Info icon SVG graphic used for tooltips or additional information.

2017

China Drug Trials ID Info icon SVG graphic used for tooltips or additional information.

CTR20170882

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Plain Language Summary Study Protocol Statistical Analysis Plan: SAP for Primary Analysis CSR Statistical Analysis Plan: SAP for Study Closeout Analysis CSR

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Plain Language Summary Study Protocol Statistical Analysis Plan: SAP for Primary Analysis CSR Statistical Analysis Plan: SAP for Study Closeout Analysis CSR